Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

• Principais autores: Hari Krishna Ananthula (Autor), Scott Parker (Autor), Erin Touchette (Autor), R. Mark Buller (Autor), Gopi Patel (Autor), Daniel Kalman (Autor), Johanna S. Salzer (Autor), Nadia Gallardo-Romero (Autor), Victoria Olson (Autor), Inger K. Damon (Autor), Tessa Moir-Savitz (Autor), Larry Sallans (Autor), Milton H. Werner (Autor), Catherine M. Sherwin (Autor), Pankaj B. Desai (Autor)
• Formato: Livro
• Publicado em: BMC, 2018-12-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Background Several tyrosine kinase inhibitors (TKIs) developed as anti-cancer drugs, also have anti-viral activity due to their ability to disrupt productive replication and dissemination in infected cells. Consequently, such drugs are attractive candidates for "repurposing" as an...